Novavax, Inc. (NVAX) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Novavax fourth quarter and full year 2025 financial results and operational highlights conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then the number one on your touchtone phone. To withdraw your question, please press star then the number one again. Please note, this event is being recorded. I would now like to turn the conference over to Louis Sané, Vice President, Investor Relations. Please go ahead. Good morning and thank you all for joining us today to discuss our fourth quarter and full year 2025 financial results and operational highlights. A press release announcing our results is available on our website at novavax.com, and an audio archive of this conference call will be available on our website later today. Please turn to slide two. Before we begin with prepared remarks, I need to remind you that this presentation includes forward-looking statements, including but not limited to statements related to Novavax's corporate strategy and operating plans, its strategic priorities, its partnerships and expectations with respect to potential royalties, milestones, cost reimbursements, the current macro and regulatory environment, the development of Novavax's clinical and preclinical product candidates, the timing and results of clinical trials, timing of regulatory filings and actions, its APA agreements and related negotiations, projected market opportunity, FULL YEAR 2026 FINANCIAL GUIDANCE AND REVENUE FRAMEWORK, AND NOVAVAX'S FUTURE FINANCIAL OR BUSINESS PERFORMANCE, INCLUDING LONG-TERM GROWTH, SAVIN...